Study lenvatinib effects by patient gender in thyroid cancer
Treatments studied
Part of Cancer, Hormones & metabolism clinical trials.
This study looks at whether safety and treatment results with lenvatinib differ between genders for people with iodine-refractory differentiated thyroid cancer. If you have already been treated with lenvatinib and meet the basic requirements, you may be asked to join after consenting.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older
- You have differentiated thyroid cancer that no longer responds to iodine treatment
- You are (or were) treated with lenvatinib for your cancer
- You can sign informed consent to take part in the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how much iodine your body absorbs after you follow a low-iodine diet before radioactive iodine treatment (131I) for thyroid cancer. It may help improve how safely and effectively this treatment is planned.
This study compares two doses of lenvatinib (24 mg vs 10 mg per day) to see which works better for people with thyroid cancer that no longer responds to radioactive iodine. It's for those whose cancer is growing or causing symptoms.
This trial tests a combination of two drugs (sinibolimab and lenvatinib) given before surgery. The goal is to shrink advanced thyroid cancer that cannot be fully removed otherwise, so that surgery can be more successful.
This trial tests a new combination of drugs for people with advanced cervical cancer that has come back or spread, and who have already tried standard treatments. It aims to see if adding these experimental drugs to lenvatinib is safe and effective.
This study looks at the effectiveness of different targeted therapy medications for people with advanced thyroid cancer that is no longer responding to standard treatment. It may help doctors understand which treatment options work best.
This trial tests lenvatinib to shrink or control advanced bone or soft tissue sarcoma that can’t be safely treated with surgery. You may be eligible if your cancer has measurable spots and you’ve had specific prior drug treatments without a durable response.
Hear when a new Differentiated Thyroid Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.